Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (191-200 of 265) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 7, 2026
S1 guideline sweat gland carcinomaMirjana Ziemer, Michael Erdmann, Abbas Agaimy, et al.
Cancers|November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg RegistryMaximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
Oncotarget|November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trialSelma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Frontiers in Oncology|June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG StudyKatharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Lancet (London, England)|July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
The British Journal of Dermatology|December 31, 2024
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanomaJan-Malte Placke, Jenny Bottek, Renata Váraljai, et al.
Pageof 27

Showing results (191-200 of 265) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 7, 2026
S1 guideline sweat gland carcinomaMirjana Ziemer, Michael Erdmann, Abbas Agaimy, et al.
Cancers|November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg RegistryMaximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
Oncotarget|November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trialSelma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Frontiers in Oncology|June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG StudyKatharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Lancet (London, England)|July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
The British Journal of Dermatology|December 31, 2024
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanomaJan-Malte Placke, Jenny Bottek, Renata Váraljai, et al.
Pageof 27